



Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements
for the year ended 31 March 2023

These annual financial statements were prepared by:
Laminin Accounting and Tax
Professional Accountants (SA)

DNL Associates Inc.
Chartered Accountants (SA)
Registered Auditor

These annual financial statements have been audited in compliance with the applicable requirements of the Companies Act of South Africa.

Issued 15 June 2023

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

General Information

Country of incorporation and domicile	South Africa
Nature of business and principal activities	Registration and marketing of pharmaceuticals
Directors	G.R.N. Simaan S. Kahanovitz V. Kumar V. Rajasekar
Registered office	3 Gwen Lane Fourth Floor Sandton South Africa 2021
Business address	3 Gwen Lane Fourth Floor Sandton South Africa 2021
Postal address	PO Box 68687 Bryanston Johannesburg South Africa 2021
Holding company	Strides Pharma Asia Pte Ltd incorporated in Singapore
Ultimate holding company	Strides Pharma Science Ltd (a company listed on the National Stock Exchange of India Limited and the BSE Limited) incorporated in India
Bankers	Investec Bank Ltd Bidvest Bank First National Bank
Auditors	DNL Associates Inc. Chartered Accountants (SA) Registered Auditor
Tax reference number	9676714141
Level of assurance	These annual financial statements have been audited in compliance with the applicable requirements of the Companies Act of South Africa.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Contents

	Page
Directors' Responsibilities and Approval	3
Directors' Report	4 - 5
Independent Auditor's Report	6 - 7
Practitioner's Compilation Report	8
Statement of Financial Position	9
Statement of Profit or Loss and Other Comprehensive Income	10
Statement of Changes in Equity	11
Statement of Cash Flows	12
Accounting Policies	13 - 27
Notes to the Annual Financial Statements	28 - 47
The following supplementary information does not form part of the annual financial statements and is unaudited:	
Detailed Income Statement	48 - 49
Tax Computation	50 - 51

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Directors' Responsibilities and Approval

The directors are required in terms of the Companies Act of South Africa to maintain adequate accounting records and are responsible for the content and integrity of the annual financial statements and related financial information included in this report. It is their responsibility to ensure that the annual financial statements fairly present the state of affairs of the company as at the end of the financial year and the results of its operations and cash flows for the period then ended, in conformity with International Financial Reporting Standards. The external auditors are engaged to express an independent opinion on the annual financial statements.

The annual financial statements are prepared in accordance with International Financial Reporting Standards and are based upon appropriate accounting policies consistently applied and supported by reasonable and prudent judgements and estimates.

The directors acknowledge that they are ultimately responsible for the system of internal financial control established by the company and place considerable importance on maintaining a strong control environment. To enable the directors to meet these responsibilities, the board of directors sets standards for internal control aimed at reducing the risk of error or loss in a cost effective manner. The standards include the proper delegation of responsibilities within a clearly defined framework, effective accounting procedures and adequate segregation of duties to ensure an acceptable level of risk. These controls are monitored throughout the company and all employees are required to maintain the highest ethical standards in ensuring the company's business is conducted in a manner that in all reasonable circumstances is above reproach. The focus of risk management in the company is on identifying, assessing, managing and monitoring all known forms of risk across the company. While operating risk cannot be fully eliminated, the company endeavours to minimise it by ensuring that appropriate infrastructure, controls, systems and ethical behaviour are applied and managed within predetermined procedures and constraints.

The directors are of the opinion, based on the information and explanations given by management, that the system of internal control provides reasonable assurance that the financial records may be relied on for the preparation of the annual financial statements. However, any system of internal financial control can provide only reasonable, and not absolute, assurance against material misstatement or loss.

The directors have reviewed the company's cash flow forecast for the year to 31 March 2024 and, in light of this review and the current financial position, they are satisfied that the company has or had access to adequate resources to continue in operational existence for the foreseeable future.

The external auditors are responsible for independently auditing and reporting on the company's annual financial statements. The annual financial statements have been examined by the company's external auditors and their report is presented on pages 6 to 7.

The annual financial statements set out on pages 9 to 51, which have been prepared on the going concern basis, were approved by the board of directors on 15 June 2023 and were signed on their behalf by:

Approval of financial statements



Gaby Simaan (Jun 15, 2023 11:06 GMT+2)

Director



Director

Johannesburg

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Directors' Report

The directors have pleasure in submitting their report on the annual financial statements of Trinity Pharma Proprietary Limited for the year ended 31 March 2023.

1. Nature of business

Trinity Pharma Proprietary Limited was incorporated in South Africa with interests in the registration and marketing of pharmaceutical products industry.

There have been no material changes to the nature of the company's business from the prior year.

2. Review of financial results and activities

The annual financial statements have been prepared in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa. The accounting policies have been applied consistently compared to the prior year.

Full details of the financial position, results of operations and cash flows of the company are set out in these annual financial statements.

3. Share capital

Issued	2023	2022	2023	2022
	Percentage held		Number of shares	
Strides Pharma Asia Pte Ltd	51.76 %	51.76 %	748	748
Juno Pharma South Africa Proprietary Limited	28.24 %	28.24 %	408	408
Asaco Trinity Proprietary Limited	20.00 %	20.00 %	289	289
	<u>100.00 %</u>	<u>100.00 %</u>	<u>1 445</u>	<u>1 445</u>

4. Control over unissued shares

The unissued ordinary shares are the subject of a general authority granted to the directors in terms of section 38 of the Companies Act of South Africa. As this general authority remains valid only until the next AGM, the shareholders will be asked at that meeting to consider an ordinary resolution placing the said unissued ordinary shares, under the control of the directors until the next AGM.

5. Dividends

No dividends were declared or paid to shareholders during the year.

6. Interests in subsidiaries

Details of material interests in subsidiaries are presented in the annual financial statements in note 6.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Directors' Report

7. Directorate

The directors in office at the date of this report are as follows:

Directors

G.R.N. Simaan

S. Kahanovitz

V. Kumar

V. Rajasekar

8. Directors' interests in shares

As at 31 March 2023, the directors of the company held direct and indirect beneficial interests consisting of 10% (2022: 10%) of its issued ordinary shares.

The register of interests of directors and others in shares of the company is available to the shareholders on request.

There have been no changes in beneficial interests that occurred between the end of the reporting period and the date of this report.

9. Holding company

The company's holding company is Strides Pharma Asia Pte Ltd which holds 51.76% (2022: 51.76%) of the company's equity. Strides Pharma Asia Pte Ltd is incorporated in Singapore.

10. Ultimate holding company

The company's ultimate holding company is Strides Pharma Science Ltd (a company listed on the National Stock Exchange of India Limited and the BSE Limited) which is incorporated in India.

11. Consolidation

Consolidated financial statements are prepared by the ultimate holding company on a group level.

12. Going concern

The annual financial statements have been prepared on the basis of accounting policies applicable to a going concern. This basis presumes that funds will be available to finance future operations and that the realisation of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of business.

13. Events after the reporting period

The directors are not aware of any material event which occurred after the reporting date and up to the date of this report.



DNL Associates Incorporated

Chartered Accountants (SA) & Registered Auditors

Registration Number: 2013/186618/21 • SAICA Firm Number: 08258422 • IRBA Practice Number: 902003

Director: AJJ de Lange – B.Com(Hons), M.Com(Tax), CA(SA), RA, Registered Tax Practitioner

280 Brooks Street, Brooklyn, Pretoria, 0181 • PO Box 2523, Brooklyn Square, 0075

Tel.: +27 12 364 0180 • Website: www.dnlinc.co.za • Email: info@dnlinc.co.za



Independent Auditor's Report

To the Shareholders of Trinity Pharma Proprietary Limited

Opinion

We have audited the annual financial statements of Trinity Pharma Proprietary Limited (the company) set out on pages 9 to 47, which comprise the statement of financial position as at 31 March 2023, statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the annual financial statements, including a summary of significant accounting policies.

In our opinion, the annual financial statements present fairly, in all material respects, the financial position of Trinity Pharma Proprietary Limited as at 31 March 2023, and its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Statements section of our report. We are independent of the company in accordance with the Independent Regulatory Board for Auditors' Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of annual financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards). We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the document titled "Trinity Pharma Proprietary Limited annual financial statements for the year ended 31 March 2023", which includes the Directors' Report as required by the Companies Act of South Africa. The other information does not include the annual financial statements and our auditor's report thereon.

Our opinion on the annual financial statements does not cover the other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the annual financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the annual financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Independent Auditor's Report

Responsibilities of the Directors for the Annual Financial Statements

The directors are responsible for the preparation and fair presentation of the annual financial statements in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa, and for such internal control as the directors determine is necessary to enable the preparation of annual financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the annual financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Annual Financial Statements

Our objectives are to obtain reasonable assurance about whether the annual financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial statements.

As part of an audit in accordance with International Standards on Auditing, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial statements, including the disclosures, and whether the annual financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


Albert G. Lange (Jun 15, 2023 13:13 GMT+2)

DNL Associates Inc.
A.J.J. de Lange
Director
Chartered Accountants (SA)
Registered Auditor

Date: 15 June 2023

280 Brooks Street
Brooklyn
Pretoria
South Africa
0181



Laminin

ACCOUNTING AND TAX

Practitioner's Compilation Report

To the Shareholders of Trinity Pharma Proprietary Limited


We have compiled the annual financial statements of Trinity Pharma Proprietary Limited, as set out on pages 9 to 47, based on information you have provided. These annual financial statements comprise the statement of financial position of Trinity Pharma Proprietary Limited as at 31 March 2023, statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

We performed this compilation engagement in accordance with International Standard on Related Services 4410 (Revised), Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist you in the preparation and presentation of these annual financial statements in accordance with International Financial Reporting Standards. We have complied with relevant ethical requirements, including principles of integrity, objectivity, professional competence and due care.

These annual financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these annual financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these annual financial statements are prepared in accordance with International Financial Reporting Standards.



Laminin Accounting and Tax
Director: C. Croukamp
Associate General Accountant (SA)

Date: 15 June 2023

FinTech Campus
81 Botterklapper Street
The Willows
Pretoria
0081

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Statement of Financial Position as at 31 March 2023

	Note(s)	2023 R	2022 R
Assets			
Non-Current Assets			
Property, plant and equipment	3	1 650 812	219 760
Right-of-use assets	4	2 674 254	-
Intangible assets	5	41 189 552	38 198 334
Investments in subsidiaries	6	100	100
Deferred tax	9	1 673 926	510 150
		47 188 644	38 928 344
Current Assets			
Inventories	10	143 274 284	99 372 522
Loans to group companies	7	7 887 895	4 651 062
Work in progress and receivables	11	1 373 243	1 715 748
Loans receivable	8	2 182 610	-
Trade and other receivables	12	131 046 346	109 912 734
Current tax receivable		1 280 311	1 137 224
Cash and cash equivalents	13	4 622 512	6 968 835
		291 667 201	223 758 125
Total Assets		338 855 845	262 686 469
Equity and Liabilities			
Equity			
Share capital	14	24 032 227	24 032 227
Retained income		64 321 822	40 562 623
		88 354 049	64 594 850
Liabilities			
Non-Current Liabilities			
Lease liabilities	4	2 384 715	-
Current Liabilities			
Trade and other payables	17	200 379 129	156 863 841
Loans from shareholders	15	11 021 130	12 927 935
Other financial liabilities	16	-	350 269
Lease liabilities	4	604 972	-
Provisions	18	2 268 248	1 742 777
Bank facilities	13	33 843 602	26 206 797
		248 117 081	198 091 619
Total Liabilities		250 501 796	198 091 619
Total Equity and Liabilities		338 855 845	262 686 469

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Statement of Profit or Loss and Other Comprehensive Income

	Note(s)	2023 R	2022 R
Revenue	19	471 989 790	398 093 476
Cost of sales		(385 963 081)	(341 037 626)
Gross profit		86 026 709	57 055 850
Other operating income	20	795 390	455 613
Other operating losses	21	(2 741 573)	(1 055 540)
Other operating expenses		(44 748 323)	(27 806 224)
Operating profit	22	39 332 203	28 649 699
Investment income	23	1 015 425	633 032
Finance costs	24	(8 093 207)	(5 008 532)
Profit before taxation		32 254 421	24 274 199
Taxation	25	(8 495 120)	(7 191 425)
Profit for the year		23 759 301	17 082 774
Other comprehensive income		-	-
Total comprehensive income for the year		23 759 301	17 082 774

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Statement of Changes in Equity

	Share capital	Share premium	Total share capital	Retained income	Total equity
	R	R	R	R	R
Balance at 01 April 2021	1 445	24 030 782	24 032 227	23 479 849	47 512 076
Profit for the year	-	-	-	17 082 774	17 082 774
Other comprehensive income	-	-	-	-	-
Total comprehensive income for the year	-	-	-	17 082 774	17 082 774
Balance at 01 April 2022	1 445	24 030 782	24 032 227	40 562 521	64 594 748
Profit for the year	-	-	-	23 759 301	23 759 301
Other comprehensive income	-	-	-	-	-
Total comprehensive income for the year	-	-	-	23 759 301	23 759 301
Balance at 31 March 2023	1 445	24 030 782	24 032 227	64 321 822	88 354 049
Note(s)	14	14	14		

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Statement of Cash Flows

	Note(s)	2023 R	2022 R
Cash flows from operating activities			
Cash receipts from customers		451 994 073	356 254 953
Cash paid to suppliers and employees		(431 276 988)	(353 519 125)
Cash generated from operations	26	20 717 085	2 735 828
Interest income		1 015 425	405 214
Dividends received		-	227 818
Finance costs		(8 093 207)	(5 008 532)
Tax paid	27	(9 801 983)	(7 531 046)
Net cash from / (utilised in) operating activities		3 837 320	(9 170 718)
Cash flows from investing activities			
Purchase of property, plant and equipment	3	(1 717 966)	(74 972)
Sale of property, plant and equipment	3	17 457	-
Cash additions to right-of-use assets	3	(2 962 027)	-
Purchase of intangible assets	5	(4 470 852)	(4 638 842)
Sale of intangible assets	5	-	1 550 000
Loans advanced to group companies		(3 236 833)	(4 446 075)
Receipts from loans receivable at amortised cost		(2 182 610)	-
Net cash utilised in investing activities		(14 552 831)	(7 609 889)
Cash flows from financing activities			
Proceeds from / (repayment of) other financial liabilities		(350 499)	282 847
Proceeds from loans from shareholders		-	821 146
Repayment of shareholders loan		(1 906 805)	-
Payment on lease liabilities		2 989 687	-
Net cash from / (utilised in) financing activities		732 383	1 103 993
Total cash movement for the year		(9 983 128)	(15 676 614)
Cash at the beginning of the year		(19 237 962)	(3 561 347)
Total cash at end of the year	13	(29 221 090)	(19 237 961)

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

Corporate information

Trinity Pharma Proprietary Limited is a private company incorporated and domiciled in South Africa.

1. Significant accounting policies

The principal accounting policies applied in the preparation of these annual financial statements are set out below.

1.1 Basis of preparation

The annual financial statements have been prepared on the going concern basis in accordance with, and in compliance with, International Financial Reporting Standards ("IFRS") and International Financial Reporting Interpretations Committee ("IFRIC") interpretations issued and effective at the time of preparing these annual financial statements and the Companies Act of South Africa of South Africa, as amended.

These annual financial statements comply with the requirements of the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and the Financial Reporting Pronouncements as issued by the Financial Reporting Standards Council.

The annual financial statements have been prepared on the historic cost convention, unless otherwise stated in the accounting policies which follow and incorporate the principal accounting policies set out below. They are presented in Rands, which is the company's functional currency.

These accounting policies are consistent with the previous period.

1.2 Significant judgements and sources of estimation uncertainty

The preparation of annual financial statements in conformity with IFRS requires management, from time to time, to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. These estimates and associated assumptions are based on experience and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Critical judgements in applying accounting policies

The critical judgements made by management, key assumptions and other sources of estimation uncertainty in applying accounting policies, apart from those involving estimations, that have the most significant effect on the amounts recognised in the financial statements, are outlined as follows:

Intangible assets

Indefinite useful life intangible assets

Significant judgement is needed by management when determining the classification of intangible assets as finite or indefinite useful life assets. An indefinite useful life intangible asset is an intangible asset where there is no foreseeable limit to the period over which the asset is expected to generate future economic benefits for the company.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.2 Significant judgements and sources of estimation uncertainty (continued)

Useful lives

The estimation of the useful lives of assets is based on historic performance as well as expectations about future use and therefore requires a significant degree of judgement to be applied by management. The actual lives of these assets can vary depending on a variety of factors, including technological innovation, product lifecycles and maintenance programmes. Management has made certain estimates with regards to the determination of estimated useful lives of intangible assets, as disclosed further in accounting policy note 1.4 - Intangible assets.

Impairment

Finite useful life intangible assets are reviewed annually, but only assessed for impairment when there are impairment indicators. Impairment testing is performed by comparing the recoverable amount to the carrying amount of the intangible asset. The recoverable amounts of the intangible assets are determined as the higher of value-in-use and fair value less costs to sell.

Key assumptions relating to this valuation include the discount rate and cash flows used to determine the value-in-use. Future cash flows are estimated based on the most recent budgets and forecasts approved by management covering a period of up to eight years and are extrapolated over the useful life of the asset to reflect the long-term plans of the company using the estimated growth rate for the specific business or product. The estimated future cash flows and discount rates used are pre-tax based on an assessment of the current risks applicable to the specific asset and/or entity and country in which it operates or the product is sold.

Management determines the expected performance of the assets based on the following:

- an assessment of existing products against past performance and market conditions;
- an assessment of existing products against existing market conditions; and
- the pipeline of products under development, applying past experiences of launch success and existing market conditions.

Amortisation rates and residual values

The company amortises its assets over their estimated useful lives. The estimation of the useful lives of assets is based on historic performance as well as expectations about future use and therefore requires a significant degree of judgement to be applied by management. The actual lives of these assets can vary depending on a variety of factors, including technological innovation, product lifecycles and maintenance programmes. Significant judgement is applied by management when determining the residual values for intangible assets. Only in the event of contractual obligations in terms of which a termination consideration is payable to the company will management apply a residual value to the intangible asset.

Impairment of investments held at cost

The company reviews and tests the carrying value of assets when events or changes in circumstances suggest that the carrying amount may not be recoverable. When such indicators exist, management determines the recoverable amount which is higher of an asset's or cash generating unit's (CGU) fair value less cost of disposal (FVLCD) and its value in use (VIU). These calculations require the use of estimates and assumptions. When it is not possible to determine the recoverable amount for an individual asset, management assesses the recoverable amount for the cash generating unit to which the asset belongs.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.2 Significant judgements and sources of estimation uncertainty (continued)

In calculating VIU, the estimated future cash flows are discounted to their present value using an after-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset/CGU. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining FVLCD, recent market transactions (where available) are taken into account. If no such transaction can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies, or other available fair value indicators. VIU does not reflect future cash flows associated with improving or enhancing an asset's performance, whereas anticipated enhancements to assets are included in FVLCD calculations.

For the key model inputs used in determining the recoverable amount refer to note 6. Impairment losses of investments are recognised in the statement of profit or loss and other comprehensive income.

1.3 Property, plant and equipment

Property, plant and equipment are tangible assets which the company holds for its own use or for rental to others and which are expected to be used for more than one year.

An item of property, plant and equipment is recognised as an asset when it is probable that future economic benefits associated with the item will flow to the company, and the cost of the item can be measured reliably.

Property, plant and equipment is initially measured at cost. Cost includes all of the expenditure which is directly attributable to the acquisition or construction of the asset, including the capitalisation of borrowing costs on qualifying assets and adjustments in respect of hedge accounting, where appropriate.

Expenditure incurred subsequently for major services, additions to or replacements of parts of property, plant and equipment are capitalised if it is probable that future economic benefits associated with the expenditure will flow to the company and the cost can be measured reliably. Day to day servicing costs are included in profit or loss in the year in which they are incurred.

Property, plant and equipment is subsequently stated at cost less accumulated depreciation and any accumulated impairment losses, except for land which is stated at cost less any accumulated impairment losses.

Depreciation of an asset commences when the asset is available for use as intended by management. Depreciation is charged to write off the asset's carrying amount over its estimated useful life to its estimated residual value, using a method that best reflects the pattern in which the asset's economic benefits are consumed by the company.

The useful lives of items of property, plant and equipment have been assessed as follows:

Item	Depreciation method	Average useful life
Furniture and fixtures	Straight line	6 years
Office equipment	Straight line	5 years
IT equipment	Straight line	3 years
Leasehold improvements	Straight line	5 years

The depreciation charge for each year is recognised in profit or loss unless it is included in the carrying amount of another asset.

Depreciation is not charged to an asset if its estimated residual value exceeds or is equal to its carrying amount.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.3 Property, plant and equipment (continued)

Where major components of an item of property, plant and equipment have significantly different patterns of consumption of economic benefits, the cost of the asset is allocated to the components and they are depreciated separately over each component's useful life.

When indicators are present that the useful lives and residual values of items of property, plant and equipment have changed since the most recent annual reporting date, they are reassessed. Any changes are accounted for prospectively as a change in accounting estimate.

Impairment tests are performed on property, plant and equipment when there is an indicator that they may be impaired. When the carrying amount of an item of property, plant and equipment is assessed to be higher than the estimated recoverable amount, an impairment loss is recognised immediately in profit or loss to bring the carrying amount in line with the recoverable amount.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its continued use or disposal. Any gain or loss arising from the derecognition of an item of property, plant and equipment, determined as the difference between the net disposal proceeds, if any, and the carrying amount of the item, is included in profit or loss when the item is derecognised.

1.4 Intangible assets

An intangible asset is recognised when:

- it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity;
- the cost of the asset can be measured reliably.

Intangible assets are initially recognised at cost.

Intangible assets are carried at cost less any accumulated amortisation and any impairment losses.

An intangible asset is regarded as having an indefinite useful life when, based on all relevant factors, there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows. Amortisation is not provided for these intangible assets, but they are tested for impairment annually and whenever there is an indication that the asset may be impaired. For all other intangible assets amortisation is provided on a straight line basis over their useful life.

The amortisation period and the amortisation method for intangible assets are reviewed every period-end.

Reassessing the useful life of an intangible asset with a finite useful life after it was classified as indefinite is an indicator that the asset may be impaired. As a result the asset is tested for impairment and the remaining carrying amount is amortised over its useful life.

Research and development costs are recognised as an expense in the period incurred.

Finite intangible assets are recognised at cost and amortised on a straight-line basis over their estimated remaining useful lives. Estimated useful lives are reviewed annually.

Development costs: expenditure on acquired patents, trademarks, dossiers, licences and know-how is capitalised. Expenditure incurred to extend the term of the patents or trademarks is capitalised. All other expenditure is charged to the statement of comprehensive income when incurred. Development costs are amortised from the commencement of the commercial sale of the product to which they relate, being the date at which all regulatory requirements necessary to commercialise the product are met.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.4 Intangible assets (continued)

Amortisation is provided to write down the intangible assets, on a straight line basis, to their residual values as follows:

Item	Depreciation method	Average useful life
Trademarks	Straight line	20 years
Dossiers	Straight line	20 years
Business models	Straight line	10 years
Computer software	Straight line	3 years

1.5 Investments in subsidiaries

Investments in subsidiaries are carried at cost less any accumulated impairment losses.

The company is not required to prepare consolidated annual financial statements because the ultimate parent company, Strides Pharma Science Ltd (formerly Strides Shasun Limited), publishes consolidated annual financial statements in accordance with Generally Accepted Accounting Practice in India.

1.6 Financial instruments

Financial instruments held by the company are classified in accordance with the provisions of IFRS 9 Financial Instruments.

Broadly, the classification possibilities, which are adopted by the company, as applicable, are as follows:

Financial assets which are equity instruments:

- Mandatorily at fair value through profit or loss.

Financial assets which are debt instruments:

- Amortised cost. (This category applies only when the contractual terms of the instrument give rise, on specified dates, to cash flows that are solely payments of principal and interest on principal, and where the instrument is held under a business model whose objective is met by holding the instrument to collect contractual cash flows); or
- Fair value through other comprehensive income. (This category applies only when the contractual terms of the instrument give rise, on specified dates, to cash flows that are solely payments of principal and interest on principal, and where the instrument is held under a business model whose objective is achieved by both collecting contractual cash flows and selling the instruments); or
- Mandatorily at fair value through profit or loss. (This classification automatically applies to all debt instruments which do not qualify as at amortised cost or at fair value through other comprehensive income); or
- Designated at fair value through profit or loss. (This classification option can only be applied when it eliminates or significantly reduces an accounting mismatch).

Financial liabilities:

- Amortised cost; or
- Designated at fair value through profit or loss. (This classification option can be applied when it eliminates or significantly reduces an accounting mismatch; the liability forms part of a group of financial instruments managed on a fair value basis; or it forms part of a contract containing an embedded derivative and the entire contract is designated as at fair value through profit or loss).

Note 30 Financial instruments and risk management presents the financial instruments held by the company based on their specific classifications.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.6 Financial instruments (continued)

All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace.

The specific accounting policies for the classification, recognition and measurement of each type of financial instrument held by the company are presented below:

Loans receivable at amortised cost

Classification

Loans to group companies (note 7) are classified as financial assets subsequently measured at amortised cost.

They have been classified in this manner because the contractual terms of these loans give rise, on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding, and the company's business model is to collect the contractual cash flows on these loans.

Recognition and measurement

Loans receivable are recognised when the company becomes a party to the contractual provisions of the loan. The loans are measured, at initial recognition, at fair value plus transaction costs, if any.

They are subsequently measured at amortised cost.

The amortised cost is the amount recognised on the loan initially, minus principal repayments, plus cumulative amortisation (interest) using the effective interest method of any difference between the initial amount and the maturity amount, adjusted for any loss allowance.

Loans denominated in foreign currencies

When a loan receivable is denominated in a foreign currency, the carrying amount of the loan is determined in the foreign currency. The carrying amount is then translated to the Rand equivalent using the spot rate at the end of each reporting period. Any resulting foreign exchange gains or losses are recognised in profit or loss in the other operating (losses) / gains (note 21).

Details of foreign currency risk exposure and the management thereof are provided in the specific notes.

Trade and other receivables

Classification

Trade and other receivables, excluding, when applicable, VAT and prepayments, are classified as financial assets subsequently measured at amortised cost (note 12).

They have been classified in this manner because their contractual terms give rise, on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding, and the company's business model is to collect the contractual cash flows on trade and other receivables.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.6 Financial instruments (continued)

Recognition and measurement

Trade and other receivables are recognised when the company becomes a party to the contractual provisions of the receivables. They are measured, at initial recognition, at fair value plus transaction costs, if any.

They are subsequently measured at amortised cost.

The amortised cost is the amount recognised on the receivable initially, minus principal repayments, plus cumulative amortisation (interest) using the effective interest method of any difference between the initial amount and the maturity amount, adjusted for any loss allowance.

Borrowings and loans from related parties

Classification

Loans from group companies (note 7), loans from shareholders (note 15) and borrowings (note 16) are classified as financial liabilities subsequently measured at amortised cost.

Recognition and measurement

Borrowings and loans from related parties are recognised when the company becomes a party to the contractual provisions of the loan. The loans are measured, at initial recognition, at fair value plus transaction costs, if any.

They are subsequently measured at amortised cost using the effective interest method.

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the amortised cost of a financial liability.

Interest expense, calculated on the effective interest method, is included in profit or loss in finance costs (note 24.)

Borrowings expose the company to liquidity risk and interest rate risk. Refer to note 30 for details of risk exposure and management thereof.

Loans denominated in foreign currencies

When borrowings are denominated in a foreign currency, the carrying amount of the loan is determined in the foreign currency. The carrying amount is then translated to the Rand equivalent using the spot rate at the end of each reporting period. Any resulting foreign exchange gains or losses are recognised in profit or loss in the other operating (losses) / gains (note 21).

Details of foreign currency risk exposure and the management thereof are provided in the specific loan notes and in the financial instruments and risk management (note 30).

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.6 Financial instruments (continued)

Trade and other payables

Classification

Trade and other payables (note 17), excluding VAT and amounts received in advance, are classified as financial liabilities subsequently measured at amortised cost.

Recognition and measurement

They are recognised when the company becomes a party to the contractual provisions, and are measured, at initial recognition, at fair value plus transaction costs, if any.

They are subsequently measured at amortised cost using the effective interest method.

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the amortised cost of a financial liability.

If trade and other payables contain a significant financing component, and the effective interest method results in the recognition of interest expense, then it is included in profit or loss in finance costs (note 24).

Trade and other payables expose the company to liquidity risk and possibly to interest rate risk. Refer to note 30 for details of risk exposure and management thereof.

Financial liabilities at fair value through profit or loss

Classification

Financial liabilities which are held for trading are classified as financial liabilities mandatorily at fair value through profit or loss. Refer to note 30.

When a financial liability is contingent consideration in a business combination, the company classifies it as a financial liability at fair value through profit or loss. Refer to note 30.

The company, does, from time to time, designate certain financial liabilities as at fair value through profit or loss. The reason for the designation is to reduce or significantly eliminate an accounting mismatch which would occur if the instruments were not classified as such; or if the instrument forms part of a group of financial instruments which are managed and evaluated on a fair value basis in accordance with a documented management strategy; or in cases where it forms part of a contract containing an embedded derivative and IFRS 9 permits the entire contract to be measured at fair value through profit or loss. Refer to note 30 for details.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.6 Financial instruments (continued)

Recognition and measurement

Financial liabilities at fair value through profit or loss are recognised when the company becomes a party to the contractual provisions of the instrument. They are measured, at initial recognition and subsequently, at fair value. Transaction costs are recognised in profit or loss.

Fair value gains or losses recognised on investments at fair value through profit or loss are included in other operating gains (losses) (note 21).

For financial liabilities designated at fair value through profit or loss, the portion of fair value adjustments which are attributable to changes in the company's own credit risk, are recognised in other comprehensive income and accumulated in equity in the reserve for valuation of liabilities, rather than in profit or loss. However, if this treatment would create or enlarge an accounting mismatch in profit or loss, then that portion is also recognised in profit or loss.

Interest paid on financial liabilities at fair value through profit or loss is included in finance costs (note 24).

Cash and cash equivalents

Cash and cash equivalents are stated at carrying amount which is deemed to be fair value.

Bank overdrafts

Bank overdrafts are initially measured at fair value, and are subsequently measured at amortised cost, using the effective interest rate method.

Derecognition

Financial assets

The company derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the company recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the company retains substantially all the risks and rewards of ownership of a transferred financial asset, the company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

Financial liabilities

The company derecognises financial liabilities when, and only when, the company obligations are discharged, cancelled or they expire. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.6 Financial instruments (continued)

Reclassification

Financial assets

The company only reclassifies affected financial assets if there is a change in the business model for managing financial assets. If a reclassification is necessary, it is applied prospectively from the reclassification date. Any previously stated gains, losses or interest are not restated.

The reclassification date is the beginning of the first reporting period following the change in business model which necessitates a reclassification.

Financial liabilities

Financial liabilities are not reclassified.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the statement of financial position if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

1.7 Tax

Current tax assets and liabilities

Current tax for current and prior periods is, to the extent unpaid, recognised as a liability. If the amount already paid in respect of current and prior periods exceeds the amount due for those periods, the excess is recognised as an asset.

Current tax liabilities (assets) for the current and prior periods are measured at the amount expected to be paid to (recovered from) the tax authorities, using the tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and liabilities

A deferred tax liability is recognised for all taxable temporary differences, except to the extent that the deferred tax liability arises from the initial recognition of an asset or liability in a transaction which at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

A deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilised. A deferred tax asset is not recognised when it arises from the initial recognition of an asset or liability in a transaction at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The corporate income tax rate will be lowered to 27 per cent (from 28 per cent) for companies with years of assessment commencing on or after 1 April 2022 and deferred tax has been adjusted accordingly where applicable.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.7 Tax (continued)

Tax expenses

Current and deferred taxes are recognised as income or an expense and included in profit or loss for the period, except to the extent that the tax arises from:

- a transaction or event which is recognised, in the same or a different period, to other comprehensive income, or
- a business combination.

Current tax and deferred taxes are charged or credited to other comprehensive income if the tax relates to items that are credited or charged, in the same or a different period, to other comprehensive income.

Current tax and deferred taxes are charged or credited directly to equity if the tax relates to items that are credited or charged, in the same or a different period, directly in equity.

Withholding taxes

Withholding taxes are withheld by foreign countries on foreign-sourced income. Excess foreign tax credits may be carried forward to the succeeding year in which it will be available for set-off against taxable income from foreign sources in that year.

1.8 Leases

The company assesses whether a contract is, or contains a lease, at the inception of the contract.

A contract is, or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

In order to assess whether a contract is, or contains a lease, management determine whether the asset under consideration is "identified", which means that the asset is either explicitly or implicitly specified in the contract and that the supplier does not have a substantial right of substitution throughout the period of use. Once management has concluded that the contract deals with an identified asset, the right to control the use thereof is considered. To this end, control over the use of an identified asset only exists when the company has the right to substantially all of the economic benefits from the use of the asset as well as the right to direct the use of the asset.

In circumstances where the determination of whether the contract is or contains a lease requires significant judgement, the relevant disclosures are provided in the significant judgments and sources of estimation uncertainty section of these accounting policies.

Short-term leases and leases of low-value assets

The company has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets. The company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

1.9 Inventories

Inventories are measured at the lower of cost and net realisable value on the first-in-first-out basis.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

The cost of inventories comprises of all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.9 Inventories (continued)

The cost of inventories of items that are not ordinarily interchangeable and goods or services produced and segregated for specific projects is assigned using specific identification of the individual costs.

The cost of inventory acquired from Heraeus Medical GmbH (Germany) is measured on the retail method in terms of an Exclusive Distribution Agreement whereby the cost of inventory is adjusted every year based on actual sales and related costs for that year.

When inventories are sold, the carrying amount of those inventories are recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realisable value, are recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

Inventories includes a "right to returned goods asset" which represents the company right to recover products from customers where customers exercise their right of return under the company returns policy. The company uses its accumulated historical experience to estimate the number of returns on a portfolio level using the expected value method. A corresponding adjustment is recognised against cost of sales.

1.10 Work in progress and receivables

Where the outcome of a contract can be estimated reliably, contract revenue and costs are recognised by reference to the stage of completion of the contract activity at the end of the reporting period, as measured by the proportion that contract costs incurred for work performed to date bear to the estimated total contract costs.

When the outcome of a contract cannot be estimated reliably, contract revenue is recognised to the extent that contract costs incurred are recoverable. Contract costs are recognised as an expense in the period in which they are incurred.

When it is probable that total contract costs will exceed total contract revenue, the expected loss is recognised as an expense immediately.

1.11 Impairment of assets

The company assesses at each end of the reporting period whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset.

If there is any indication that an asset may be impaired, the recoverable amount is estimated for the individual asset. If it is not possible to estimate the recoverable amount of the individual asset, the recoverable amount of the cash-generating unit to which the asset belongs is determined.

An impairment loss of assets carried at cost less any accumulated depreciation or amortisation is recognised immediately in profit or loss.

An entity assesses at each reporting date whether there is any indication that an impairment loss recognised in prior periods for assets other than goodwill may no longer exist or may have decreased. If any such indication exists, the recoverable amounts of those assets are estimated.

1.12 Share capital and equity

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.12 Share capital and equity (continued)

Ordinary shares are recognised at par value and classified as 'share capital' in equity. Any amounts received from the issue of shares in excess of par value is classified as 'share premium' in equity. Dividends are recognised as a liability in the company in which they are declared.

1.13 Employee benefits

Short-term employee benefits

The cost of short-term employee benefits, (those payable within 12 months after the service is rendered, such as paid vacation leave and sick leave, bonuses, and non-monetary benefits such as medical care), are recognised in the period in which the service is rendered and are not discounted.

Defined contribution plans

Payments to defined contribution retirement benefit plans are charged as an expense as they fall due.

1.14 Provisions and contingencies

Provisions are recognised when:

- the company has a present obligation as a result of a past event;
- it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation;
- a reliable estimate can be made of the obligation.

The amount of a provision is the present value of the expenditure expected to be required to settle the obligation.

Where some or all of the expenditure required to settle a provision is expected to be reimbursed by another party, the reimbursement shall be recognised when, and only when, it is virtually certain that reimbursement will be received if the entity settles the obligation. The reimbursement shall be treated as a separate asset. The amount recognised for the reimbursement shall not exceed the amount of the provision.

Provisions are not recognised for future operating losses.

If an entity has a contract that is onerous, the present obligation under the contract shall be recognised and measured as a provision.

Contingent assets and contingent liabilities are not recognised.

1.15 Revenue from contracts with customers

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The company recognises revenue when it transfers control of a product or service to a customer. Revenue is stated at the invoice amount and is exclusive of value added taxation.

Revenue is recognised based on the completion of performance obligations and an assessment of when control is transferred to the customer.

The following indicators are used by the company in determining when control has passed to the customer:

- the company has a right to payment for the product or service;
- the customer has legal title to the product;
- the company has transferred physical possession of the product to the customer;
- the customer has the significant risk and rewards of ownership of the product; and
- the customer has accepted the product.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.15 Revenue from contracts with customers (continued)

Revenue is measured based on the consideration specified in a contract with a customer and in compliance with legislated pricing. The company evaluates the following control indicators among others when determining whether it is acting as a principal or agent in the transactions with customers and recording revenue on a net basis:

- the company is primarily responsible for fulfilling the promise to provide the specified goods or service;
- the company has inventory risk before the specified goods or service has been transferred to a customer or after transfer of control to the customer; and
- the company has discretion in establishing the price for the specified goods or service, excluding pricing set according to regulations.

No significant element of financing is deemed present as the sales are made with credit terms less than one year.

The company recognises revenue from the following major sources:

Sale of goods

Revenue is recognised at a point in time when control of the products supplied has transferred, being when the products are delivered to the customer. Delivery occurs when the products has been dispatched to the specific location, the risks of obsolescence and loss have been transferred and the customer accepted the products in accordance with the sales contract. Revenue is recorded at the price specified in the contract in compliance with regulated pricing in regulated markets, net of discounts and value added tax. Revenue and receivables are recorded when control of the products are transferred as this is the point in time that the consideration is unconditional as only the passage of time is required before payment is due.

Co-marketing fees

Co-marketing fees are revenue that the company receives in exchange for providing a service to arrange specified sales of speciality, branded and generic pharmaceuticals to a customer. Revenue is based on an upfront agreed upon fee driven by sales volumes. The sales volumes are products delivered at a point in time to customers. Revenue and receivables are recorded on co-marketing fees when performance obligations according to the contract for arranging sales to customers have been met and the products have been delivered to the customer. Delivery occurs when the products have been dispatched to the specific location, the risks of obsolescence and loss have been transferred and the customer accepted the goods in accordance with the co-marketing agreement.

1.16 Cost of sales

When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realisable value, is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

The related cost of providing services recognised as revenue in the current period is included in cost of sales.

1.17 Borrowing costs

All other borrowing costs are recognised as an expense in the period in which they are incurred.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Accounting Policies

1.18 Translation of foreign currencies

Foreign currency transactions

A foreign currency transaction is recorded, on initial recognition in Rands, by applying to the foreign currency amount the spot exchange rate between the functional currency and the foreign currency at the date of the transaction.

At the end of the reporting period:

- foreign currency monetary items are translated using the closing rate;
- non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction; and
- non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous annual financial statements are recognised in profit or loss in the period in which they arise.

When a gain or loss on a non-monetary item is recognised to other comprehensive income and accumulated in equity, any exchange component of that gain or loss is recognised to other comprehensive income and accumulated in equity. When a gain or loss on a non-monetary item is recognised in profit or loss, any exchange component of that gain or loss is recognised in profit or loss.

Cash flows arising from transactions in a foreign currency are recorded in Rands by applying to the foreign currency amount the exchange rate between the Rand and the foreign currency at the date of the cash flow.

Exchange rates at year end were:

1 USD = R17.8013

1 EUR = R19.3631

1 GBP = R22.0185

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

2. New Standards and Interpretations

2.1 Standards and interpretations effective and adopted in the current year

In the current year, the company has adopted the following standards and interpretations that are effective for the current financial year and that are relevant to its operations:

Standard/ Interpretation:	Effective date: Years beginning on or after	Expected impact:
• Annual Improvement to IFRS Standards 2018-2020: Amendments to IFRS 1	01 January 2022	Unlikely there will be a material impact
• Reference to the Conceptual Framework: Amendments to IFRS 3	01 January 2022	Unlikely there will be a material impact
• Annual Improvement to IFRS Standards 2018-2020: Amendments to IFRS 9	01 January 2022	Unlikely there will be a material impact
• Property, Plant and Equipment: Proceeds before Intended Use: Amendments to IAS 16	01 January 2022	Unlikely there will be a material impact
• Annual Improvement to IFRS Standards 2018-2020: Amendments to IAS 41	01 January 2022	Unlikely there will be a material impact

2.2 Standards and interpretations not yet effective or relevant

The following standards and interpretations have been published and are mandatory for the company's accounting periods beginning on or after 1 January 2023 or later periods but are not relevant to its operations:

Standard/ Interpretation:	Effective date: Years beginning on or after	Expected impact:
• Lease liability in a sale and leaseback	01 January 2024	Unlikely there will be a material impact
• Initial application of IFRS 17 and IFRS 9 - Comparative information	01 January 2023	Unlikely there will be a material impact
• Deferred tax related to assets and liabilities arising from a single transaction - Amendments to IAS 12	01 January 2023	Unlikely there will be a material impact
• Disclosure of accounting policies: Amendments to IAS 1 and IFRS Practice Statement 2.	01 January 2023	Unlikely there will be a material impact
• Definition of accounting estimates: Amendments to IAS 8	01 January 2023	Unlikely there will be a material impact
• Classification of Liabilities as Current or Non-Current - Amendment to IAS 1	01 January 2023	Unlikely there will be a material impact

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

3. Property, plant and equipment

	2023			2022		
	Cost or revaluation	Accumulated depreciation	Carrying value	Cost or revaluation	Accumulated depreciation	Carrying value
Furniture and fixtures	1 118 026	(76 307)	1 041 719	47 491	(38 075)	9 416
Motor vehicles	304 064	(304 063)	1	304 064	(301 229)	2 835
Office equipment	234 021	(136 431)	97 590	193 255	(135 161)	58 094
IT equipment	524 237	(207 142)	317 095	431 030	(299 160)	131 870
Leasehold improvements	218 506	(24 106)	194 400	50 884	(33 346)	17 538
Text books	21 327	(21 320)	7	21 327	(21 320)	7
Total	2 420 181	(769 369)	1 650 812	1 048 051	(828 291)	219 760

Reconciliation of property, plant and equipment - 2023

	Opening balance	Additions	Disposals / scrappings	Depreciation	Total
Furniture and fixtures	9 416	1 112 897	(6 838)	(73 756)	1 041 719
Motor vehicles	2 835	-	-	(2 834)	1
Office equipment	58 094	71 813	(78)	(32 239)	97 590
IT equipment	131 870	314 750	(14 674)	(114 851)	317 095
Leasehold improvements	17 538	218 506	(12 658)	(28 986)	194 400
Text books	7	-	-	-	7
	219 760	1 717 966	(34 248)	(252 666)	1 650 812

Reconciliation of property, plant and equipment - 2022

	Opening balance	Additions	Disposals / scrappings	Depreciation	Total
Furniture and fixtures	14 939	-	-	(5 523)	9 416
Motor vehicles	63 702	-	-	(60 867)	2 835
Office equipment	87 657	-	-	(29 563)	58 094
IT equipment	124 205	74 972	-	(67 307)	131 870
Leasehold improvements	27 763	-	-	(10 225)	17 538
Text books	7	-	-	-	7
	318 273	74 972	-	(173 485)	219 760

Property, plant and equipment encumbered as security

The following assets have been encumbered as security for the secured long-term borrowings:

Wesbank financing / Bookvalue of vehicle	-	2 835
--	---	-------

Refer to note 16 for details of property, plant and equipment encumbered as security for borrowings. The loan was repaid during the financial year.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

3. Property, plant and equipment (continued)

Registers with details of property, plant and equipment are available for inspection by shareholders or their duly authorised representatives at the registered office of the company.

4. Right-of-use assets and lease liabilities

Details pertaining to leasing arrangements, where the company is lessee are presented below:

Net carrying amounts of right-of-use assets

The carrying amounts of right-of-use assets are included in the following line items:

Buildings	2 674 254	-
-----------	-----------	---

Depreciation recognised on right-of-use assets

Depreciation recognised on each class of right-of-use assets, is presented below. It includes depreciation which has been expensed in the total depreciation charge in profit or loss (note 22), as well as depreciation which has been capitalised to the cost of other assets.

Buildings	287 773	-
-----------	---------	---

Other disclosures

Interest expense on lease liabilities	165 262	-
Expenses on short-term leases included in operating expenses	177 980	305 758
Interest received on deposit on lease	(10 252)	-

Lease liabilities

The maturity analysis of lease liabilities is as follows:

Within one year	642 731	-
Two to five years	3 280 997	-
	3 923 728	-
Less finance charges component	(934 041)	-
Present value of minimum lease payments	2 989 687	-
Non-current liabilities	2 384 715	-
Current liabilities	604 972	-
	2 989 687	-

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023			2022		
	Cost / Valuation	Accumulated amortisation and impairments	Carrying value	Cost / Valuation	Accumulated amortisation and impairments	Carrying value
Trademarks	8 040	(3 127)	4 913	8 040	(2 571)	5 469
Business models	600 000	(599 999)	1	600 000	(599 999)	1
Dossiers	44 760 280	(3 575 642)	41 184 638	40 289 428	(2 096 564)	38 192 864
Total	45 368 320	(4 178 768)	41 189 552	40 897 468	(2 699 134)	38 198 334

Reconciliation of intangible assets - 2023

	Opening balance	Additions	Disposals	Amortisation	Total
Trademarks	5 469	-	-	(556)	4 913
Business models	1	-	-	-	1
Dossiers	38 192 864	11 520 507	(7 049 656)	(1 479 077)	41 184 638
	38 198 334	11 520 507	(7 049 656)	(1 479 633)	41 189 552

Reconciliation of intangible assets - 2022

	Opening balance	Additions	Disposals	Amortisation	Total
Trademarks	6 024	-	-	(555)	5 469
Business models	54 678	-	-	(54 677)	1
Dossiers	35 673 346	4 638 842	(1 000 064)	(1 119 260)	38 192 864
	35 734 048	4 638 842	(1 000 064)	(1 174 492)	38 198 334

Capitalised expenditure on dossiers

In line with Strides' group policy, only license and regulatory body registration costs are to be capitalised against dossiers and all other costs are expensed when incurred.

A number of dossiers have not yet been brought into use at year end and therefore no amortisation has been provided on these intangible assets.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

		2023	2022	
		R	R	
6. Investments in subsidiaries				
Name of company	% holding 2023	% holding 2022	Carrying amount 2023	Carrying amount 2022
Apollo Life Sciences Holdings Proprietary Limited	100.00 %	100.00 %	100	1 559 673
			100	1 559 673
Impairment of investment in subsidiaries			-	(1 559 573)
			100	100

The subsidiary is incorporated in South Africa and shares the year end of the company.

The carrying amounts of subsidiaries are shown net of impairment losses.

Impairment testing: Investment in Apollo Life Sciences Holdings Proprietary Limited - Information about key sources of estimation uncertainty

The company based its impairment calculation on detailed budgets and forecasts based on management's and the group's expectations of revenue and growth. The estimated cash flows are based on expected future contracted revenue, operating costs, staff costs and capital expenditure. At year end the company assessed the investment and found the carrying amount to be reasonable.

The following were the key model inputs used in determining the recoverable amount:

- assumed discount rate of 20%;
- assumed long-term sustainable growth rate of 7%.

In 2018 an impairment charge of R19 461 359 arose on the investment in Apollo Life Sciences Holdings Proprietary Limited resulting in its carrying amount of R21 021 032 being written down to a recoverable amount of R1 559 673.

In 2022 it was decided that Apollo Life Sciences Holdings Proprietary Limited be wound down and as a result the investment in the entity was further impaired with R1 559 573.

7. Loans to group companies

Fellow subsidiary

Strides Pharma (SA) Proprietary Limited	7 887 895	4 651 062
---	-----------	-----------

The loan bears interest at the prime rate and has no fixed terms of repayment. Strides Pharma (SA) Proprietary Limited provided a limited resource guarantee limited to R6 000 000 to Investec in terms of all payments due and owing by the Trinity Pharma to Investec, limited to the proceeds in terms of the cession of debtors, including a session of Strides' debtors book in favour of Investec.

8. Loans receivable

Loans receivable are presented at amortised cost, which is net of loss allowance, as follows:

Loan-Heman Martiz	2 182 610	-
-------------------	-----------	---

The loan bears interest at the prime lending rate and is payable on demand.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023 R	2022 R
9. Deferred tax		
Deferred tax liability		
Prepayments	(84 889)	(58 766)
Right of use asset	(722 049)	-
Total deferred tax liability	(806 938)	(58 766)
Deferred tax asset		
Employee provisions	612 427	472 657
Provision for stock impairments	861 008	-
Lease liability	841 600	-
Work in progress	165 829	96 259
Total deferred tax asset	2 480 864	568 916
<p>The deferred tax assets and the deferred tax liability relate to income tax in the same jurisdiction, and the law allows net settlement. Therefore, they have been offset in the statement of financial position as follows:</p>		
Deferred tax liability	(806 938)	(58 766)
Deferred tax asset	2 480 864	568 916
Total net deferred tax asset	1 673 926	510 150
Reconciliation of deferred tax asset		
At beginning of year	510 150	20 215
Movement in temporary differences	1 163 776	489 935
	1 673 926	510 150
10. Inventories		
Pharmaceutical products - Third Parties	27 077 502	21 259 620
Pharmaceutical products - Trinity Pharma	109 069 309	72 671 095
Goods in transit	10 316 390	6 727 202
	146 463 201	100 657 917
Inventories (write-downs)	(3 188 917)	(1 285 395)
	143 274 284	99 372 522
Inventory held for third parties		

The inventory held for third parties are owned by the company. They are however separately managed and controlled in terms of the agreement with third parties on whose behalf the inventory is sold.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023 R	2022 R
10. Inventories (continued)		
Inventory pledged as security		
Inventory was pledged as security for the Investec Bank Ltd's trade facility in terms of a General Notarial Bond. At period end the facility had a balance of R33 826 430 (2022: R26 166 513). The total facility available is R35 000 000.		
11. Work in progress and receivables		
Work in progress and receivables	1 373 243	1 715 748
Advances received in excess of work completed are included in trade and other payables.		
12. Trade and other receivables		
Financial instruments:		
Trade receivables	129 855 456	109 204 673
Creditors with debit balances	266 952	467 226
Loss allowance	-	-
Trade receivables at amortised cost	130 122 408	109 671 899
Deposits	186 662	1 184
Staff loans	234 899	22 000
Non-financial instruments:		
Prepayments	502 377	217 651
Total trade and other receivables	131 046 346	109 912 734

Trade receivables are non-interest bearing and are generally on terms of 30 to 90 days.

Customer credit risk is managed according to the Company's established policy, procedures and controls relating to customer credit risk management. Outstanding customer receivables are regularly monitored and followed up. At 31 March 2023, the company had 13 (2022: 11) customers that owed it more than R2 000 000 each, and accounted for approximately 92% (2022: 90%) of all the receivables outstanding and 10.4% (2022: 12.1%) of the total balances outstanding were outstanding for longer than 60 days. No doubt exist regarding the collectibility of these balances.

An impairment analysis is performed at each reporting date using a single loss rate based on an assessment of the Group's historical bad debts and the company's own historical bad debts. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets disclosed in Note 30. The Company does not hold collateral as security except for Strides Pharma SA Proprietary Limited, a fellow subsidiary of the holding company, which provided a limited resource guarantee to Investec in terms of all payments due and owing by the company to Investec, limited to the proceeds in terms of the cession of debtors (see below), including a session of Strides' debtors book in favour of Investec. The Company evaluates the concentration of risk with respect to trade receivables as low, as it has a large number of unrelated customers from various industries, operating independently in the market.

Based on this and the historical data which reflects that no amounts have been impaired on trade receivables over the past 5 years, the single loss rate were determined as nil% and as a result the Expected Credit Loss allowance is Nil.

There have not been any notable observable changes in payment behaviour nor to the economic environment of our customers.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023	2022
	R	R
12. Trade and other receivables (continued)		
Trade and other receivables pledged as security		
Trade and other receivables were pledged as security for the Investec Bank Ltd's trade facility in terms of a first cession of the debtors book. At period end the facility had a balance of R33 826 430 (2022: R26 166 513). The total facility available is R35 000 000.		
13. Cash and cash equivalents		
Cash and cash equivalents consist of:		
Cash on hand	2 175	98
Bank balances	4 620 337	6 968 737
Credit cards	(17 172)	(40 284)
Bank overdraft	(33 826 430)	-
Revolving bank facility	-	(25 999 621)
Accrued interest on Revolving bank facility	-	(166 892)
	(29 221 090)	(19 237 962)
Cash and cash equivalents	4 622 512	6 968 835
Bank facilities	(33 843 602)	(26 206 797)
	(29 221 090)	(19 237 962)

The revolving bank facility was closed during the financial year and replaced by a bank overdraft.

Bank balances includes the following foreign denominated bank accounts:

USD	\$	298	\$	265
GBP	£	222	£	258

The Investec Bank Ltd - general banking facility is repayable on demand and bears interest at the prime rate (11.25% at year end).

Secured by:

- Letter of Support from the shareholders in line with their pro-rata shareholding in the company (thus Strides' guarantee limited to R18 116 000);
- Limited personal guarantee by the director GRN Simaan – limited to R1 500 000;
- A general notarial bond over inventory amounting to R30 000 000;
- Primary cession of the debtors' book.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023 R	2022 R
14. Share capital		
Authorised		
4 000 Ordinary shares of R1 each	4 000	4 000
<p>Unissued ordinary shares are under the control of the directors in terms of a resolution of members passed at the last annual general meeting. This authority remains in force until the next annual general meeting.</p>		
Issued		
1 445 Ordinary shares of R1 each	1 445	1 445
Share premium	24 030 782	24 030 782
	24 032 227	24 032 227
15. Loans from shareholders		
Asaco Trinity Proprietary Limited	2 249 009	2 588 193
Juno Pharma South Africa Proprietary Limited	3 137 904	3 700 464
Strides Pharma Asia Pte Ltd	5 634 217	6 639 278
	11 021 130	12 927 935
<p>During July 2019 the company obtained loan funding from its shareholders in order to meet its business requirements. These loans are unsecured and bears interest at the prime rate (between 7.75% and 11.25% during the year). During January 2021 the original loans were settled in full including interest. Further loans were obtained from the shareholders during June 2020 on similar terms. These loans are repayable by March 2024. The loan from Strides Pharma Asia Pte Ltd was approved by the South African Reserve Bank.</p>		
Split between non-current and current portions		
Current liabilities	11 021 130	12 927 935
16. Other financial liabilities		
Held at amortised cost		
WesBank finance - motor vehicle	-	5 372
<p>The loan was settled during the year (refer to note 3).</p>		
Forward exchange contracts	-	344 897
	-	350 269
Split between non-current and current portions		
Current liabilities	-	350 269

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023 R	2022 R
16. Other financial liabilities (continued)		
Forward exchange contracts		
<p>Certain forward exchange contracts have been entered into for the purposes of managing foreign currency risk related to the purchase of inventory. The net market value of all forward exchange contracts at reporting date is calculated by comparing the forward exchange contracted rates to the equivalent market foreign exchange rates at reporting date. The present value of these net market values are then calculated using the appropriate currency specific discount curve.</p>		
17. Trade and other payables		
Financial instruments:		
Trade payables	138 305 536	104 996 762
Amounts due to subsidiaries	100 000	-
Accrual for stock received not yet invoiced	674 837	6 713 446
Employees taxes	528 857	297 116
Accrued expenses	861 396	1 728 970
Employee benefits accrued	35 056	-
Royalties fees	57 118 796	37 327 808
Other payables	1 321 518	-
Non-financial instruments:		
VAT	1 433 133	5 799 739
	200 379 129	156 863 841

18. Provisions

Reconciliation of provisions - 2023

	Opening balance	Additions	Utilised during the year	Total
Bonus provision	974 168	1 449 827	(974 168)	1 449 827
Employee related provisions	768 609	818 421	(768 609)	818 421
	1 742 777	2 268 248	(1 742 777)	2 268 248

Reconciliation of provisions - 2022

	Opening balance	Additions	Utilised during the year	Total
Bonus provision	902 740	646 577	(575 149)	974 168
Employee related provisions	552 068	786 304	(569 763)	768 609
	1 454 808	1 432 881	(1 144 912)	1 742 777

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

		2023	2022
		R	R
19. Revenue			
	Revenue from contracts with customers		
	Sale of goods	429 810 584	362 924 029
	Rendering of services	619 956	1 352 294
	Sales as agent for third parties	41 559 250	33 817 153
		<u>471 989 790</u>	<u>398 093 476</u>
20. Other operating income			
	Skills development refunds	29 868	23 129
	Marketing fee recoveries	765 522	432 484
		<u>795 390</u>	<u>455 613</u>
21. Other operating (losses) / gains			
	(Losses) /gains on disposals, scrappings and settlements		
	Property, plant and equipment	3 (18 497)	-
	Intangible assets	5 1 578	549 937
		<u>(16 919)</u>	<u>549 937</u>
	Foreign exchange losses		
	Net foreign exchange loss	(2 724 654)	(45 904)
	Fair value losses		
	Investment in subsidiaries	6 -	(1 559 573)
	Total other operating losses	<u>(2 741 573)</u>	<u>(1 055 540)</u>

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023 R	2022 R
22. Operating profit		
Operating profit for the year is stated after charging (crediting) the following, amongst others:		
Auditor's remuneration - external		
Fees (current year includes interim fee)	305 653	266 733
Accounting, tax, secretarial and other services	33 325	28 860
	<u>338 978</u>	<u>295 593</u>
Employee costs		
Salaries, wages, bonuses and other benefits	22 506 712	15 107 012
Leases		
Short-term leases	177 980	305 758
Total lease expenses	<u>177 980</u>	<u>305 758</u>
Depreciation and amortisation		
Depreciation of property, plant and equipment	252 666	173 485
Depreciation of right-of-use assets	287 773	-
Amortisation of intangible assets	1 479 634	1 174 492
Total depreciation and amortisation	<u>2 020 073</u>	<u>1 347 977</u>
23. Investment income		
Dividend income		
Group entities:		
Subsidiaries - Local	-	227 818
Interest income		
Investments in financial assets:		
Bank and other cash	-	30 429
Interest on lease deposit	10 253	-
Interest on loan: Strides Pharma (SA) Proprietary Limited	762 099	374 785
Interest on loan: H Maritz	243 073	-
Total interest income	<u>1 015 425</u>	<u>405 214</u>
Total investment income	<u>1 015 425</u>	<u>633 032</u>

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023 R	2022 R
24. Finance costs		
Shareholders	1 205 655	1 504 762
Lease liabilities	165 262	-
Revolving bank facility	1 062 622	1 083 964
Current borrowings (trade financing and debtors discounting)	5 659 668	2 419 806
Total finance costs	8 093 207	5 008 532
25. Taxation		
Major components of the tax expense		
Current		
Local income tax - current period	9 658 896	7 681 360
Deferred		
Local deferred tax - current period	(1 163 776)	(489 935)
	8 495 120	7 191 425
Reconciliation of the tax expense		
Reconciliation between accounting profit and tax expense		
Accounting profit	32 254 421	24 274 199
Tax at the applicable tax rate of 27% (2022: 28%)	8 708 694	6 796 776
Tax effect of adjustments on taxable income		
Depreciation on leasehold improvements	7 826	2 864
Dividend income	-	(63 789)
Capital loss on impairment of investment	-	436 680
Learnership allowance	(221 400)	-
Impact on deferred tax due to decrease in tax rate	-	18 895
	8 495 120	7 191 426
Estimated capital losses on impairment of investment (refer to note 6) for which no deferred tax asset has been recognised.	21 020 932	21 020 932

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023	2022
	R	R
26. Cash generated from operations		
Profit before taxation	32 254 421	24 274 199
Adjustments for:		
Depreciation and amortisation	2 020 073	1 347 977
Losses (gains) on disposals, scrappings and settlements of assets and liabilities	16 919	(549 937)
Losses on foreign exchange	2 724 654	45 904
Dividends received (trading)	-	(227 818)
Interest income	(1 015 425)	(405 214)
Finance costs	8 093 207	5 008 532
Fair value losses	-	1 559 573
Movements in provisions	525 471	287 969
Changes in working capital:		
Inventories	(43 901 762)	(29 433 436)
Trade and other receivables	(21 133 612)	(47 453 692)
Work in progress and receivables	-	2 102 499
Work in progress and receivables	342 505	-
Trade and other payables	40 790 634	46 179 272
	20 717 085	2 735 828
27. Tax paid / Receivable		
Balance at beginning of the year	1 137 224	1 287 538
Current tax for the year recognised in profit or loss	(9 658 896)	(7 681 360)
Balance at end of the year	(1 280 311)	(1 137 224)
	(9 801 983)	(7 531 046)

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

28. Directors' emoluments

Executive

2023

Directors' emoluments	Basic salary	Expense re- imbursement	Total
Services as director or prescribed officer			
G.R.N. Simaan	1 468 674	85 933	1 554 607

2022

Directors' emoluments	Basic salary	Expense re- imbursement	Total
Services as director or prescribed officer			
G.R.N. Simaan	2 265 334	79 434	2 344 768

29. Related parties

Relationships

Ultimate holding company	Strides Pharma Science Ltd (a company listed on the National Stock Exchange of India Limited and the BSE Limited)
Holding company	Strides Pharma Asia Pte Ltd
Subsidiaries	Refer to note 6
Common control of directors	Kahma Healthcare Group Proprietary Limited (S. Kahanovitz) Asaco Trinity Proprietary Limited (GRN Simaan)
Fellow subsidiaries and associates	Other entities related to Strides Group Other entities related to Kahma Group
Members of key management	Refer to Directors' Report

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023	2022
	R	R
29. Related parties (continued)		
Related party balances		
Loan accounts - Owing (to) / by related parties		
Strides Pharma Asia Pte Ltd	(5 634 217)	(6 639 278)
Asaco Trinity Proprietary Limited	(2 249 009)	(2 588 193)
Juno Pharma South Africa Proprietary Limited	(3 137 904)	(3 700 464)
Strides Pharma (SA) Proprietary Limited	7 887 895	4 651 062
Amounts included in Trade Receivable / (Trade Payable) regarding related parties		
Apollo Life Sciences Holdings Proprietary Limited - trade payable	-	(348 154)
Arco Lab Private Limited (India)	(69 229)	(56 625)
Strides Pharma (SA) Proprietary Limited, South Africa - trade payable	(5 856 523)	(11 178 416)
Strides Pharma (SA) Proprietary Limited, South Africa - trade receivable	103 363	6 929 400
Strides Pharma Science Limited - trade payable	(3 457 664)	(7 355 804)
Strides Pharma Science Limited - trade receivable	-	227 679
Strides Pharma Asia Pte Ltd - trade payable	(114 188)	(16 733)
Juno Pharma South Africa Proprietary Limited	(5 423)	66 198
K2 Medical Proprietary Limited	(15 772)	(73 397)
Kahma Healthcare Group Proprietary Limited	(47 546)	(67 261)
Kahma Biotech Proprietary Limited - receivable	1 087 329	(1 960 886)
Juno Pharmaceuticals (Canada) Corp	104 971	-
Kahma Biotech Proprietary Limited - payable	(1 741 640)	-
Strides Pharma Global Pte Ltd - payable	(466 187)	-
Related party transactions		
Interest and corporate guarantees to / (from) related parties		
Kahma Healthcare Group Proprietary Limited	81 179	52 106
Asaco Trinity Proprietary Limited	243 308	201 131
Strides Pharma Asia Pte Ltd	618 727	421 284
Strides Pharma (SA) Proprietary Limited, South Africa	(762 099)	(374 785)
Juno Pharma South Africa Proprietary Limited	262 440	235 634
Purchases from / (sales to) related parties		
Strides Pharma (SA) Proprietary Limited, South Africa - sales	(742 207)	(781 490)
Strides Pharma (SA) Proprietary Limited, South Africa - purchases	20 735 581	14 948 880
Strides Pharma Global Pte Ltd - purchases	3 638 675	1 910 381
Juno Pharma South Africa Proprietary Limited	(227 640)	-
Kahma Healthcare Group Proprietary Limited	(3 356)	-
The Vaccine Bureau Proprietary Limited	(7 207)	-
Strides Pharma UK Ltd	(9 052)	-
Juno Pharmaceuticals (Canada)	(1 073 185)	-
Kahma Biotech Proprietary Limited - sales	(5 796 577)	(5 945 046)
Kahma Biotech Proprietary Limited - purchases	271 050	2 008 265
Strides Pharma Science Limited	3 208 501	8 659 557

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

	2023	2022
	R	R
29. Related parties (continued)		
Recharges, recoveries, expenses and fees (to) / from related parties		
Arco Lab Private Limited	270 000	270 000
Juno Pharma South Africa Proprietary Limited	-	(414 007)
K2 Medical Proprietary Limited	215 646	607 488
Kahma Biotech Proprietary Limited	-	(68 280)
Strides Pharma (SA) Proprietary Limited, South Africa	241 181	-
Kahma Healthcare Group Proprietary Limited	214 670	188 611
Strides Pharma Asia Pte Ltd	-	95 502
Dividends paid to / (received from) related parties		
Apollo Life Sciences Holdings Proprietary Limited	-	(227 818)
Advances from related parties		
Apollo Life Sciences Holdings Proprietary Limited	100 000	-

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

30. Financial instruments and risk management

Categories of financial instruments

Categories of financial assets

2023

	Note(s)	Amortised cost	Fair value
Loans to group companies	7	7 887 895	-
Loans receivable	8	2 182 610	-
Trade and other receivables	12	130 543 969	130 543 969
Work in progress and receivables	11	1 373 243	1 373 243
Cash and cash equivalents	13	4 622 512	4 622 512
		146 610 229	136 539 724

2022

	Note(s)	Amortised cost	Fair value
Investments in subsidiaries	6	100	-
Loans to group companies	7	4 651 062	-
Trade and other receivables	12	109 695 083	109 695 083
Work in progress and receivables	11	1 715 748	1 715 748
Cash and cash equivalents	13	6 968 835	6 968 835
		123 030 828	118 379 666

Categories of financial liabilities

2023

	Note(s)	Amortised cost	Leases	Fair value
Trade and other payables	17	198 945 994	-	-
Loans from shareholders	15	11 021 130	-	-
Lease liabilities	4	-	2 989 687	-
		209 967 124	2 989 687	-

2022

	Note(s)	Amortised cost	Leases	Fair value
Trade and other payables	17	151 064 100	-	-
Loans from shareholders	15	12 927 935	-	-
Other financial liabilities at fair value	16	-	-	350 269
		163 992 035	-	350 269

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

30. Financial instruments and risk management (continued)

Capital risk management

The company's objective when managing capital (which includes share capital, borrowings, working capital and cash and cash equivalents) is to maintain a flexible capital structure that reduces the cost of capital to an acceptable level of risk and to safeguard the company's ability to continue as a going concern while taking advantage of strategic opportunities in order to maximise stakeholder returns sustainably.

The company monitors capital utilising a number of measures, including the gearing ratio. The gearing ratio is calculated as net borrowings (total borrowings less cash) divided by shareholders' equity.

Loans from shareholders	15	11 021 130	12 927 935
Financial liabilities at fair value	16	-	350 269
Lease liabilities		2 989 687	-
Trade and other payables	17	200 379 127	156 863 839
Total borrowings		214 389 944	170 142 043
Bank overdraft (cash and cash equivalents)	13	29 221 090	19 237 962
Net borrowings		243 611 034	189 380 005
Equity		88 354 050	64 594 849
Gearing ratio		276 %	293 %

Financial risk management

Overview

The company's activities expose it to a variety of financial risks: market risk (including currency risk, fair value interest rate risk, cash flow interest rate risk and price risk), credit risk and liquidity risk which are managed by the directors.

Credit risk

Credit risk is the risk of financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations.

The company is exposed to credit risk on loans receivable, debt instruments at fair value through other comprehensive income, trade and other receivables, contract receivables, lease receivables, cash and cash equivalents, loan commitments and financial guarantees.

Credit risk for exposures other than those arising on cash and cash equivalents, are managed by making use of credit approvals, limits and monitoring. The company only deals with reputable counterparties with consistent payment histories. Sufficient collateral or guarantees are also obtained when necessary. Each counterparty is analysed individually for creditworthiness before terms and conditions are offered. The analysis involves making use of information submitted by the counterparties as well as external bureau data (where available). Counterparty credit limits are in place and are reviewed and approved by credit management committees. The exposure to credit risk and the creditworthiness of counterparties is continuously monitored.

Credit risk exposure arising on cash and cash equivalents is managed by the group through dealing with well-established financial institutions with high credit ratings.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Notes to the Annual Financial Statements

30. Financial instruments and risk management (continued)

Credit loss allowances for expected credit losses are recognised for all debt instruments, but excluding those measured at fair value through profit or loss. Credit loss allowances are also recognised for loan commitments and financial guarantee contracts.

Liquidity risk

The company is exposed to liquidity risk, which is the risk that the company will encounter difficulties in meeting its obligations as they become due.

Cash flow forecasts are prepared and adequate utilised borrowing facilities are monitored.

Foreign currency risk

The company operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the Euro, US Dollar and British Pound. Foreign exchange risk arises from future commercial transactions, and recognised assets and liabilities. The company does hedge foreign exchange fluctuations from time to time based on the assessed risk. The company reviews its foreign currency exposure, including commitments on an ongoing basis.

Interest rate risk

Fluctuations in interest rates impact on the value of investments and financing activities, giving rise to interest rate risk.

There have been no significant changes in the interest rate risk management policies and processes since the prior reporting period.

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Detailed Income Statement

	Note(s)	2023 R	2022 R
Revenue	19	471 989 790	398 093 476
Cost of sales			
Opening stock		(93 930 715)	(66 729 037)
Purchases		(428 179 177)	(368 239 304)
Closing stock		136 146 811	93 930 715
		(385 963 081)	(341 037 626)
Gross profit		86 026 709	57 055 850
Other operating income			
Skills development refunds		29 868	23 129
Marketing fee recoveries		765 522	432 484
	20	795 390	455 613
Other operating losses			
(Losses) / gains on disposal of assets or settlement of liabilities		(16 919)	549 937
Foreign exchange losses		(2 724 654)	(45 904)
Fair value losses		-	(1 559 573)
	21	(2 741 573)	(1 055 540)
Expenses (Refer to page 49)		(44 748 323)	(27 806 224)
Operating profit	22	39 332 203	28 649 699
Investment income	23	1 015 425	633 032
Finance costs	24	(8 093 207)	(5 008 532)
Profit before taxation		32 254 421	24 274 199
Taxation	25	(8 495 120)	(7 191 425)
Profit for the year		23 759 301	17 082 774

Trinity Pharma Proprietary Limited

(Registration number 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Detailed Income Statement

	Note(s)	2023 R	2022 R
Other operating expenses			
Advertising		11 980 480	5 349 719
Amortisation		1 479 634	1 174 492
Auditor's remuneration - external audit	22	338 978	295 593
Bank charges		95 072	90 034
B-BBEE spend		429 500	280 000
Cleaning		27 129	33 944
Computer expenses		1 097 268	670 147
Consulting and professional fees		1 575 749	1 511 817
Depreciation		540 439	173 485
Donations		27 600	814 513
Employee costs		22 506 712	15 107 012
Entertainment		33 160	17 981
Regularly fees		850 547	-
General office expenses		18 103	191
Insurance		668 525	410 753
Motor vehicle expenses		35 362	20 761
Municipal expenses		48 107	68 460
Postage		28 533	11 210
Printing and stationery		79 148	30 484
Repairs and maintenance		22 042	21 528
Security		18 554	25 339
Short-term leases		177 980	305 758
Staff welfare		242 912	114 465
Subscriptions		1 128 147	689 509
Telephone and fax		217 599	149 634
Training		61 216	141 990
Travel - local		935 953	244 587
Travel - overseas		83 874	52 818
		44 748 323	27 806 224

Trinity Pharma Proprietary Limited

(Taxpayer reference number 9676714141)

(Registration number: 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Tax Computation

	2023 R	2022 R
Net profit per income statement	32 254 421	24 274 199
Permanent differences (Non-deductible/Non taxable items)		
Depreciation on leasehold improvements	28 986	10 226
Dividends received - Not taxable	-	(227 818)
Impairment on investment - Capital loss (Ringfenced)	-	1 559 573
Learnership Allowance (s12H)	(820 000)	-
	<u>(791 014)</u>	<u>1 341 981</u>
Temporary differences		
Allowance for future expenditure (s24C) - prior year	-	4 214 526
Work in progress not yet invoiced/accrued	(1 373 243)	(1 630 911)
Reversal of work in progress claim in previous year	1 630 911	3 818 247
Amounts previously taxed as received in advance	-	(4 958 266)
Depreciation according to financial statements	223 680	161 987
Wear and tear allowance (s11(e))	(223 680)	(161 987)
Prepaid expenditure not limited by s23H - current year	(314 403)	(217 651)
Reversal of prepaid expenditure allowed in prior year	217 651	97 649
Provision for stock write offs - current year	3 188 917	-
Provision for stock write offs - prior year	-	(191 076)
Reversal for marketing spent not deductible prior year	-	388 958
Provision for leave pay and bonus not deductible current year	2 238 822	1 721 154
Reversal of leave pay provisions previously raised	(1 721 154)	(1 425 382)
Provision for commissions not deductible current year	29 426	29 426
Reversal of provision for commissions previously raised	(29 426)	(29 426)
Depreciation according to financial statements	287 772	-
Interest paid in respect of capitalised leased assets	155 009	-
	<u>4 310 282</u>	<u>1 817 248</u>
Taxable income for 2023	<u>35 773 689</u>	<u>27 433 428</u>
Tax thereon @ 27% in the Rand	<u>9 658 896</u>	

Trinity Pharma Proprietary Limited

(Taxpayer reference number 9676714141)

(Registration number: 2003/020397/07)

Annual Financial Statements for the year ended 31 March 2023

Tax Computation

	2023	2022
	R	R
Reconciliation of tax balance		
Amount prepaid at the beginning of year	(1 137 224)	
Tax prepaid for the current year:		
Normal tax		
Per calculation	9 658 896	
1st provisional payment	(3 787 800)	
2nd provisional payment	(6 014 183)	
	(143 087)	
Amount prepaid at the end of year	(1 280 311)	

Trinity Pharma_Audited Financials_March 2023


Final Audit Report

2023-06-15


Created:	2023-06-15
By:	Marizette Bezuidenhout (marizette@trinitypharma.co.za)
Status:	Signed
Transaction ID:	CBJCHBCAABAAfafvyxNig3x5PQ-Ls0Fv79pmoAOB6DrA

"Trinity Pharma_Audited Financials_March 2023" History

-  Document created by Marizette Bezuidenhout (marizette@trinitypharma.co.za)
2023-06-15 - 8:17:24 AM GMT- IP address: 197.184.176.63
-  Document emailed to gaby.simaan@trinitypharma.co.za for signature
2023-06-15 - 8:18:25 AM GMT
-  Email viewed by gaby.simaan@trinitypharma.co.za
2023-06-15 - 9:05:05 AM GMT- IP address: 169.239.225.215
-  Signer gaby.simaan@trinitypharma.co.za entered name at signing as Gaby Simaan
2023-06-15 - 9:06:16 AM GMT- IP address: 62.244.174.38
-  Document e-signed by Gaby Simaan (gaby.simaan@trinitypharma.co.za)
Signature Date: 2023-06-15 - 9:06:18 AM GMT - Time Source: server- IP address: 62.244.174.38
-  Document emailed to selwyn.kahanovitz@kahmagroup.co.za for signature
2023-06-15 - 9:06:20 AM GMT
-  Email viewed by selwyn.kahanovitz@kahmagroup.co.za
2023-06-15 - 10:16:29 AM GMT- IP address: 49.180.14.1
-  Signer selwyn.kahanovitz@kahmagroup.co.za entered name at signing as Selwyn Kahanovitz
2023-06-15 - 10:20:14 AM GMT- IP address: 49.180.14.1
-  Document e-signed by Selwyn Kahanovitz (selwyn.kahanovitz@kahmagroup.co.za)
Signature Date: 2023-06-15 - 10:20:16 AM GMT - Time Source: server- IP address: 49.180.14.1
-  Document emailed to Albert de Lange (albert@dnlinc.co.za) for signature
2023-06-15 - 10:20:18 AM GMT
-  Email viewed by Albert de Lange (albert@dnlinc.co.za)
2023-06-15 - 10:47:21 AM GMT- IP address: 41.114.16.51

 Document e-signed by Albert de Lange (albert@dnlinc.co.za)

Signature Date: 2023-06-15 - 11:13:05 AM GMT - Time Source: server- IP address: 41.71.9.106

 Agreement completed.

2023-06-15 - 11:13:05 AM GMT